119 related articles for article (PubMed ID: 9620905)
21. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
23. Role of the physiochemical properties of mucus in the protection of the respiratory epithelium.
Girod S; Zahm JM; Plotkowski C; Beck G; Puchelle E
Eur Respir J; 1992 Apr; 5(4):477-87. PubMed ID: 1563506
[TBL] [Abstract][Full Text] [Related]
24. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases.
Girod S; Galabert C; Lecuire A; Zahm JM; Puchelle E
Pediatr Pulmonol; 1992 May; 13(1):22-7. PubMed ID: 1589308
[TBL] [Abstract][Full Text] [Related]
25. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
Sun F; Tai S; Lim T; Baumann U; King M
Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
[TBL] [Abstract][Full Text] [Related]
26. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
27. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis.
Homnick DN; Marks JH; Rubin BK
J Aerosol Med; 2007; 20(1):45-9. PubMed ID: 17388752
[TBL] [Abstract][Full Text] [Related]
28. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
29. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
30. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
Shibuya Y; Wills PJ; Cole PJ
Respiration; 2001; 68(6):615-9. PubMed ID: 11786718
[TBL] [Abstract][Full Text] [Related]
31. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy.
App EM; King M; Helfesrieder R; Köhler D; Matthys H
Am Rev Respir Dis; 1990 Mar; 141(3):605-12. PubMed ID: 2310093
[TBL] [Abstract][Full Text] [Related]
32. Mucus structure and properties in cystic fibrosis.
Rubin BK
Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
[TBL] [Abstract][Full Text] [Related]
34. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum.
Lethem MI; James SL; Marriott C
Am Rev Respir Dis; 1990 Nov; 142(5):1053-8. PubMed ID: 2240828
[TBL] [Abstract][Full Text] [Related]
35. RhDNase before airway clearance therapy improves airway patency in children with CF.
van der Giessen LJ; de Jongste JC; Gosselink R; Hop WC; Tiddens HA
Pediatr Pulmonol; 2007 Jul; 42(7):624-30. PubMed ID: 17534979
[TBL] [Abstract][Full Text] [Related]
36. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of human recombinant DNase in pediatric patients with cystic fibrosis.
Furuya ME; Lezana-Fernández JL; Vargas MH; Hernández-Sierra JF; Ramírez-Figueroa JL
Arch Med Res; 2001; 32(1):30-4. PubMed ID: 11282177
[TBL] [Abstract][Full Text] [Related]
38. A new method to improve the clinical evaluation of cystic fibrosis patients by mucus viscoelastic properties.
Tomaiuolo G; Rusciano G; Caserta S; Carciati A; Carnovale V; Abete P; Sasso A; Guido S
PLoS One; 2014; 9(1):e82297. PubMed ID: 24404129
[TBL] [Abstract][Full Text] [Related]
39. Ferret tracheal mucus rheology, clearability and volume following administration of substance P or methacholine.
De Sanctis GT; Rubin BK; Ramirez O; King M
Eur Respir J; 1993 Jan; 6(1):76-82. PubMed ID: 7678818
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
